- Bora Pharmaceuticals has approved the acquisition of MacroGenics’ GMP manufacturing operations and CDMO business for US$122.5 million, with up to an additional $5 million in contingent payments.
- The deal includes a biologics manufacturing facility in Rockville, Maryland, and is expected to expand Bora’s end-to-end biologics CDMO and contract manufacturing capabilities.
Bora Pharmaceuticals has announced that its Board of Directors approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics for US$122.5 million, subject to customary working capital adjustments. The agreement also includes contingent consideration of up to $5 million linked to future customer orders.
The transaction includes a biologics drug substance manufacturing facility in Rockville, Maryland, and an associated warehousing centre in Frederick, Maryland. Bora said it will also enter into a long-term CDMO Service Agreement with MacroGenics following completion of the acquisition.
According to the company, the Rockville site has operated as an outsource manufacturing partner since 2022 and contains five 2,000-litre and two 500-litre single-use bioreactors, alongside integrated quality control and analytical laboratories. The facility has undergone inspections by both the U.S. FDA and Japan’s PMDA. Bora stated that the acquisition is expected to add commercial-stage monoclonal antibody programmes, clinical-stage projects and an existing manufacturing backlog to its Bora Biologics business.
“This acquisition marks a pivotal step in strengthening Bora’s integrated biologics CDMO platform in the United States. With the addition of the Rockville site, Bora Biologics total drug substance capacity would be 20,000-liter (SUB) and Bora Group will integrate our in-house DS (Drug Substance) and DP (Drug Product) capabilities and network investments over the next 12 to 18 months to offer global biotech customers a seamless offering allowing customers to advance programmes from development through commercial supply with one single partner.”
Bobby Sheng, Chairman and CEO of Bora Group
Bora said it plans to operate the Rockville facility alongside Tanvex Biopharma, which manages the Group’s biologics CDMO operations under the Bora Biologics brand. The company added that the transaction is intended to expand its biologics contract manufacturing network and strengthen its integrated drug substance and drug product offering for biotechnology customers.
